Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts.
The incidence of hepatobiliary complications of cystic fibrosis (CF) has been increasing in parallel with the rate of survival. Detection of hepatic involvement remains a problem, as liver function tests, serum bile acid determinations, and ultrasonography do not permit an early diagnosis. The pathogenesis of cholelithiasis has been elucidated in the past few years. However, the mechanism leading to the pathognomonic CF lesion, focal biliary cirrhosis, is still unknown. There are indications that mucus plugging may be the ancestral lesion and the triggering factor. The possibility that correction of the abnormalities of bile acid metabolism could slow the progress or prevent CF cirrhosis is discussed in light of recent experimental data.
D000293:Adolescent; D000328:Adult; D000375:Aging; D001647:Bile Acids and Salts / Q000097:blood / Q000378:metabolism; D001660:Biliary Tract Diseases / Q000209:etiology*; D002648:Child; D002675:Child, Preschool; D002769:Cholelithiasis / Q000209:etiology / Q000473:pathology; D003550:Cystic Fibrosis / Q000150:complications*; D005227:Fatty Acids / Q000378:metabolism; D005705:Gallbladder Diseases / Q000209:etiology* / Q000473:pathology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008105:Liver Cirrhosis, Biliary / Q000209:etiology* / Q000473:pathology; D008107:Liver Diseases / Q000209:etiology*; D008111:Liver Function Tests; D008297:Male
D001647:Bile Acids and Salts; D005227:Fatty Acids